Key result
H-FABP demonstrated a sensitivity of 89.7% and specificity of 68% for the early diagnosis of AMI, superior to initial cTnI and CK-MB.
Why the study?
Does H-FABP determination improve the early diagnosis of acute myocardial infarction in patients presenting with acute chest pain compared to cTnI and CK-MB?
Observational (n=54)
Does H-FABP determination improve the early diagnosis of acute myocardial infarction in patients presenting with acute chest pain compared to cTnI and CK-MB?
H-FABP is a highly sensitive early biomarker for acute myocardial infarction, particularly within the first 6 hours of symptom onset, outperforming initial cTnI and CK-MB.
Answers are grounded in this paper and cite their sources.
H-FABP may aid early AMI detection in chest pain; hypothesis-generating and should not change practice without prospective validation.
BACKGROUND: Heart-type fatty acid-binding protein (H-FABP) is an emerging biomarker, which was found to be sensitive for the early diagnosis of acute myocardial infarction (AMI). We prospectively investigated the usefulness of H-FABP determination for the evaluation of acute chest pain in patients arriving at the emergency department. METHODS: Fifty-four patients presenting with acute ischemic chest pain were evaluated. H-FABP was estimated at admission using latex-enhanced immunoturbidimetric assay. Serial cardiac troponin I (cTnI), creatinine kinase-MB (CK-MB) determination, ischemia workup with stress testing, and/or coronary angiogram (CAG) were performed according to standard protocols. RESULTS: The sensitivity and specificity of H-FABP was 89.7% and 68%, for cTnI it was 62.1% and 100%, and for CK-MB it was 44.8% and 92%, respectively for diagnosis of AMI. The sensitivity of H-FABP was found to be far superior to initial cTnI and CK-MB, for those seen within 6h (100% vs. 46.1%, 33% respectively). On further evaluation of patients with positive H-FABP and negative cTnI, 71.4% of the patients had significant lesion on CAG, indicating ischemic cause of H-FABP elevation. Six patients with normal cTnI and CK-MB with high H-FABP had ST elevation on subsequent ECGs and were taken for primary angioplasty. CONCLUSION: H-FABP is a highly sensitive biomarker for the early diagnosis of AMI. H-FABP as early marker and cTnI as late marker would be the ideal combination to cover the complete diagnostic window for AMI. Detection of myocardial injury by H-FABP may also be applied in patients with unstable angina. H-FABP can also be used as a marker for early detection of STEMI before the ECG changes become apparent.
No takes yet. Share an insight, caveat, or question.
Vupputuri et al. (2015) conducted an observational in Acute chest pain (n=54). H-FABP determination vs. cTnI and CK-MB was evaluated on Sensitivity for diagnosis of AMI. H-FABP demonstrated a sensitivity of 89.7% and specificity of 68% for the early diagnosis of AMI, superior to initial cTnI and CK-MB.
Synapse has enriched 10 related papers. Consider them for comparative context: